The Impact of New Driver Mutations on Treatment of NSCLC

Video Library —June 15, 2021
Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Lauren Welch, MSN, NP-C, AOCNP, discusses the impact that the discovery of new actionable molecular targets and oncogenic drivers has had on treatment of NSCLC, with at least 6 new targets, all with approved targeted therapies. She suggests that patients have better outcomes with targeted therapies upfront, so that identification of these targets early through broad NGS testing is essential in extending survival in patients with NSCLC.
Related Articles
Overview of Current Imaging Modalities in Prostate Cancer
Neal Shore, MD, FACS
|
Video Library
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
Quality of Life with Combination Therapy in Advanced Renal-Cell Cancer
Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, Virginia Seery, CRNP, MSN
|
Video Library
Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss strategies for addressing patients’ concerns about how combination therapy may impact their activities of daily living and quality of life.
The Impact of Real-World Data on Efficacy and Safety of Agents for Advanced Renal-Cell Cancer
Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, Virginia Seery, CRNP, MSN
|
Video Library
The last 10 to 15 years has seen important advances in the management of advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss how real-world efficacy and safety data influence the conversations they have with their patients with advanced renal-cell carcinoma regarding treatment options.
Last modified: June 16, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code